SUMMARY
Brokerage Radar: Kotak Institutional Equities says 'reduce' Divi's Laboratories while CLSA has downgraded its rating on shares of Muthoot Finance and cut EPS estimates. Here are the top brokerage calls for the day:
1 / 6
Citi on ONGC | A recent spike in crude prices keeps sentiment positive for now for ONGC, said Citi. Sentiment could quickly reverse if and when crude prices come off, the brokerage firm added while maintaining its 'sell' recommendation.
2 / 6Jefferies on Divi's Laboratories | The company's stock is trading at a 32 percent premium to Gland and other large-cap contract manufacturers, Jefferies said maintaining its 'hold' rating on Divi's Lab shares.
3 / 6Kotak Institutional Equities on Divi's Lab | Valuations adequately capture the company's growth narrative from a medium-term perspective, said Kotak Equities. The brokerage firm has retained its 'reduce' recommendation on the stock.
4 / 6CLSA on Apollo Hospitals | Fundraise in Apollo HealthCo is a key catalyst for significant upside hereon, believes CLSA. However, the brokerage firm has cut FY22-24 EBITDA by 3-5 percent on lower margin assumptions for pharmacy.
5 / 6Citi on Persistent Systems | The acquisition of Data Glove Assets is expected to dilute EBIT margin by 75 basis points in FY23, said Citi maintaining its 'sell' call on the company's stock.
6 / 6CLSA on Muthoot Finance | CLSA has downgraded its rating on shares of Muthoot Finance to 'outperform' and has cut EPS estimates by 3-9 percent as higher auction spoils the party.
